View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 7, 2021updated 11 Jul 2022 2:22pm

Slope raises funds to advance decentralised clinical trials

The tech-driven infrastructure solution of Slope alleviates operational setbacks and delays in trial management processes. 

‍Clinical operations solution company Slope has raised $20m in a Series A funding round led by international venture capital firm New Enterprise Associates (NEA) to expedite go-to-market efforts and further progress into decentralised and direct-to-patient clinical trials.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The technology-powered infrastructure solution of Slope links ClinOps teams, research sites, contract research organisations (CROs), vendors, patients and labs, in real-time.

This connection is facilitated through a 21 CFR Part 11 compliant software platform, obtaining clinical supply chain demand data at the patient level.

The data can be used along with research-oriented workflows for operational complexity coordination and automation.

Slope CEO and co-founder Rust Felix said: “Finding an investment partner with first-hand knowledge of the problems caused by the inefficiencies of current clinical trial supply chain management processes was a key success factor for us at Slope.

“With its expansive life sciences portfolio and deep domain expertise, NEA was at the top of our list.”

Slope’s solution tackles the operational setbacks and delays caused by manual, spreadsheet-powered clinical trial management processes.

Software-aided workflows steered by real-time supply chain data automatically organise thousands of logistical transactions that happen throughout the trial lifecycle while obtaining and recording significant metadata.

This guarantees a completely traceable chain of custody, irrespective of the trial design, for all therapies, devices, lab kits, samples and equipment as they move across a supply chain of the trial.

In 2018, the company unveiled its free inventory management solution for clinical research sites.

A solution was launched in 2019 for clinical trial sponsors and CROs that links clinical operations groups to operational data happening at the patient level.

This year, Slope launched a fulfilment centre in Richmond, Virginia, US, producing smart lab kits that aid in real-time inventory management.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena